Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: Experience from acrostudy

Endocrine Practice

Volumn 21, Issue 3, 2015, Pages 264-274

  Freda, Pamela ^a   Gordon, Murray ^b   Kelepouris, Nicky ^c   Jonsson, Peter ^c   Koltowska Haggstrom, Maria ^d   Van Der Lely, A ^e  

^a College of Phys and Surg ^*  (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c PFIZER INC   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; GADOLINIUM; HYPOPHYSIS HORMONE; LUTEINIZING HORMONE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE;

ACROMEGALY; ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ADULT; AGED; ALANINE AMINOTRANSFERASE LEVEL; APPARENT LIFE THREATENING EVENT; ARTICLE; ASPARTATE AMINOTRANSFERASE LEVEL; BRAIN HEMORRHAGE; CAROTID ARTERY; CLINICAL EVALUATION; COHORT ANALYSIS; COMORBIDITY ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DESCRIPTIVE RESEARCH; DIABETES MELLITUS; DISEASE SURVEILLANCE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTRON SPIN RESONANCE; EVALUATION AND FOLLOW UP; FEMALE; FOLLITROPIN RELEASE; GASTROINTESTINAL HEMORRHAGE; GIGANTISM; GLUCOSE HOMEOSTASIS; HEART ANEURYSM; HEART VENTRICLE FIBRILLATION; HEMATOMA; HOSPITALIZATION; HUMAN; HYPERSENSITIVITY; HYPERTENSION; INJECTION SITE IRRITATION; LABORATORY; LIPODYSTROPHY; LIPOHYPERTROPHY; LIVER FUNCTION TEST; LONG TERM CARE; LONGITUDINAL STUDY; MACROADENOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PANCREATITIS; PATIENT COMPLIANCE; PITUITARY STALK; PROLACTIN BLOOD LEVEL; PRURITUS; RADIOLOGIST; RETROSPECTIVE STUDY; SKIN ALLERGY; SLEEP DISORDERED BREATHING; SUDDEN CARDIAC DEATH; THYROTROPIN BLOOD LEVEL; TUMOR VOLUME; VASOPRESSIN BLOOD LEVEL; YOUNG ADULT; ADOLESCENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; CHILD; INFANT; LIVER; PATHOPHYSIOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME; VERY ELDERLY;

ACROMEGALY; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INFANT; INSULIN-LIKE GROWTH FACTOR I; LIVER; MALE; MIDDLE AGED; RECEPTORS, SOMATOTROPIN; TREATMENT OUTCOME;

EID: 85017330557     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP14330.OR     Document Type: Article

References (29)

1. Swearingen B, Barker FG 2nd, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998;83:3419-3426
2. Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg. 1998;89:353-358
3. van der Lely AJ, de Herder WW, Lamberts SW. The role of radiotherapy in acromegaly. J Clin Endocrinol Metab. 1997;82:3185-3186
4. Barkan AL, Halasz I, Dornfeld KJ, et al. Pituitary irradiation is ineffective in normalizing plasma insulinlike growth factor I in patients with acromegaly. J Clin Endocrinol Metab. 1997;82:3187-3191
5. van der Klaauw AA, Biermasz NR, Hoftijzer HC, Pereira AM, Romijn JA. Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly. Clin Endocrinol (Oxf). 2008;69:123-128
6. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83:374-378
7. Colao A, Cappabianca P, Caron P, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol (Oxf). 2009;70:757-768
8. Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007;66:859-868
9. Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary. 2010;13:18-28
10. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90:4465-4473
11. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342:1171-1177
12. van der Lely AJ, Hutson RK, Trainer PJ, et al. Longterm treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358:1754-1759
13. Trainer PJ. ACROSTUDY: the first 5 years. Eur J Endocrinol. 2009;161 Suppl 1:S19-24
14. Trainer PJ. ACROSTUDY: an overview. Horm Res. 2007; 68 Suppl 5:68-69
15. van der Lely AJ, Biller BM, Brue T, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab. 2012;97:1589-1597
16. Luger A, Feldt-Rasmussen U, Abs R, Gaillard RC, Buchfelder M, Trainer P, Brue T. Lessons learned from 15 years of KIMS and 5 years of ACROSTUDY. Horm Res Paediatr. 2011;76 Suppl 1:33-38
17. Brue T, Castinetti F, Lundgren F, Koltowska-Haggstrom M, Petrossians P, ACROSTUDY investigators. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY. Eur J Endocrinol. 2009;161 Suppl 1:S11-17
18. Buchfelder M, Weigel D, Droste M, et al. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol. 2009;161:27-35
19. Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: longterm safety for up to 4.5 years (median 2.2 years) of followup in 86 patients. Eur J Endocrinol. 2009;160:529-533
20. Trainer PJ, Ezzat S, DSouza GA, Layton G, Strasburger CJ. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf). 2009;71:549-557
21. Buhk JH, Jung S, Psychogios MN, et al. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab. 2010;95:552-558
22. van der Lely AJ, Muller A, Janssen JA, et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab. 2001;86:478-481
23. Frohman LA, Bonert V. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy. Pituitary. 2007;10:283-289
24. Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol. 2007;156:75-82
25. Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005;90:5684-5691
26. Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol. 2006;154:467-477
27. Jimenez C, Burman P, Abs R, et al. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur J Endocrinol. 2008; 159:517-523
28. Marazuela M, Paniagua AE, Gahete MD, et al. Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. J Clin Endocrinol Metab. 2011;96:E251-259
29. Buchfelder M, Schlaffer S, Droste M, et al. The German ACROSTUDY: past and present. Eur J Endocrinol. 2009; 161 Suppl 1:S3-S10